Martin Sebastian

12.0k total citations · 3 hit papers
117 papers, 5.8k citations indexed

About

Martin Sebastian is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Martin Sebastian has authored 117 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 89 papers in Oncology, 74 papers in Pulmonary and Respiratory Medicine and 29 papers in Molecular Biology. Recurrent topics in Martin Sebastian's work include Lung Cancer Treatments and Mutations (67 papers), Lung Cancer Research Studies (37 papers) and Colorectal Cancer Treatments and Studies (22 papers). Martin Sebastian is often cited by papers focused on Lung Cancer Treatments and Mutations (67 papers), Lung Cancer Research Studies (37 papers) and Colorectal Cancer Treatments and Studies (22 papers). Martin Sebastian collaborates with scholars based in Germany, United States and United Kingdom. Martin Sebastian's co-authors include Vassiliki A. Papadimitrakopoulou, Tony Mok, Suresh S. Ramalingam, Frances A. Shepherd, Yi‐Long Wu, Myung‐Ju Ahn, Willemijn S.M.E. Theelen, Hiroaki Akamatsu, Helen Mann and Yong He and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Martin Sebastian

101 papers receiving 5.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

2016 2.4k citations Tony Mok, Yi‐Long Wu et al. profile →
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

2012 816 citations Martin Sebastian, Martin Reck et al. Journal of Clinical Oncology profile →
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

2012 500 citations Martin Reck, Martin Sebastian et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Martin Sebastian Germany	27	4.1k	3.3k	1.7k	945	930	117	5.8k
Robert M. Jotte United States	31	5.6k 1.4×	4.0k 1.2×	1.4k 0.8×	1.0k 1.1×	744 0.8×	111	6.9k
Hiroshi Nokihara Japan	40	3.9k 0.9×	3.3k 1.0×	1.7k 1.0×	484 0.5×	935 1.0×	237	5.9k
Piotr Serwatowski Germany	15	4.0k 1.0×	3.5k 1.1×	1.0k 0.6×	760 0.8×	626 0.7×	28	5.3k
Naoyuki Nogami Japan	30	5.9k 1.4×	5.4k 1.6×	1.4k 0.8×	757 0.8×	969 1.0×	149	7.4k
Shengxiang Ren China	46	4.4k 1.1×	3.8k 1.2×	2.4k 1.4×	1.1k 1.2×	1.8k 1.9×	249	7.3k
Noemı́ Reguart Spain	41	2.9k 0.7×	2.6k 0.8×	2.5k 1.4×	419 0.4×	875 0.9×	175	5.5k
Shunichi Sugawara Japan	36	4.2k 1.0×	3.5k 1.0×	1.1k 0.6×	448 0.5×	548 0.6×	209	5.4k
Manuel Cobo Spain	30	3.6k 0.9×	3.4k 1.0×	1.3k 0.8×	565 0.6×	1.1k 1.2×	219	5.3k
Aleksandra Szczęsna Poland	23	4.4k 1.1×	4.2k 1.3×	1.2k 0.7×	381 0.4×	665 0.7×	73	5.8k
Michael Smylie Canada	30	7.2k 1.8×	4.4k 1.3×	2.4k 1.4×	1.6k 1.7×	1.0k 1.1×	92	9.1k

Countries citing papers authored by Martin Sebastian

Since Specialization

Citations

This map shows the geographic impact of Martin Sebastian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Sebastian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Sebastian more than expected).

Fields of papers citing papers by Martin Sebastian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Sebastian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Sebastian. The network helps show where Martin Sebastian may publish in the future.

Co-authorship network of co-authors of Martin Sebastian

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Sebastian. A scholar is included among the top collaborators of Martin Sebastian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Sebastian. Martin Sebastian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Reck, Martin, Daniel Martín, Stefan Rieken, et al.. (2025). Efficacy and safety of immune checkpoint inhibition combined with concurrent chemoradiotherapy in patients with stage III unresectable non-small cell lung cancer: A systematic review and meta-analysis. European Journal of Cancer. 218. 115266–115266. 3 indexed citations

Sebastian, Martin, Wilfried Eberhardt, Steffen Dörfel, et al.. (2024). Patient‐reported outcomes in advanced NSCLC before and during the COVID‐19 pandemic: Real‐world data from the German prospective CRISP Registry (AIO‐TRK‐0315). International Journal of Cancer. 154(11). 1967–1978.

Fischer, Rieke, Julie George, Hans Anton Schloesser, et al.. (2024). BIOLUMA: A phase II trial of nivolumab and ipilimumab in lung cancer—Results from the SCLC TMB^high cohort.. Journal of Clinical Oncology. 42(16_suppl). 8099–8099. 1 indexed citations

Chromik, Jörg, Sebastian Wolf, Julius C. Enßle, et al.. (2024). Real‐world effectiveness of first‐line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapy. European Journal Of Haematology. 113(5). 623–630. 4 indexed citations

Sebastian, Martin, et al.. (2023). Lung Cancer Resection after Immunochemotherapy Versus Chemotherapy in Oligometastatic Nonsmall Cell Lung Cancer. The Thoracic and Cardiovascular Surgeon. 71(8). 656–663. 3 indexed citations

Evers, Georg, Daniel C. Christoph, Wolfgang M. Brueckl, et al.. (2023). 1300P Treatment and clinical outcome in recurrent/refractory locally advanced NSCLC following chemoradiotherapy and consolidative durvalumab. Annals of Oncology. 34. S749–S749.

Frost, Nikolaj, Annalen Bleckmann, Frank Griesinger, et al.. (2023). Rationale and Design of the Phase II ANTELOPE Study of Atezolizumab, Carboplatin and nab-Paclitaxel vs. Pembrolizumab, Platinum and Pemetrexed in TTF-1 Negative, Metastatic Lung Adenocarcinoma (AIO-TRK-0122). Clinical Lung Cancer. 24(6). 568–572.

Stratmann, Jan, Marcel Wiesweg, Wilfried Eberhardt, et al.. (2023). Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting. Journal of Cancer Research and Clinical Oncology. 149(11). 9243–9252. 2 indexed citations

Stratmann, Jan, Martin Sebastian, Maximilian Rauch, et al.. (2022). Pulmonary Resection after Radiosurgery and Neoadjuvant Immunochemotherapy for NSCLC Patients with Synchronous Brain Metastasis—A Case Series of Three Patients. Current Oncology. 29(4). 2225–2239. 1 indexed citations

10.

George, Julie, Andreas H. Scheel, Hans Anton Schloesser, et al.. (2022). 1028P BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response – results from the NSCLC cohort. Annals of Oncology. 33. S1025–S1025. 1 indexed citations

11.

Griesinger, Frank, Arnd Nusch, Marcel Reiser, et al.. (2018). Molecular testing, frequency of molecular alteraions and first-line treatment of patients with non-small cell lung carcinoma (NSCLC) in Germany. First results from the prospective German Registry CRISP (AIO-TRK-0315). Pneumologie. 72(S 01). S57–S57. 2 indexed citations

12.

Sebastian, Martin, Anna Rydén, Andrew Walding, & Vassiliki A. Papadimitrakopoulou. (2018). Patient-reported symptoms possibly related to treatment with osimertinib or chemotherapy for advanced non-small cell lung cancer. Lung Cancer. 122. 100–106. 11 indexed citations

13.

Riedel, Richard, Anna Kron, Sebastian Michels, et al.. (2017). Impact of next generation TKI and co-occurring mutations in ALK-positive NSCLC patients: Results of the Network Genomic Medicine. Annals of Oncology. 28. v474–v474.

14.

Sebastian, Martin, James Chih‐Hsin Yang, Lecia V. Sequist, et al.. (2014). Analysis of overall survival (OS) in two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut). European Respiratory Journal. 44(Suppl 58). 1929–1929. 6 indexed citations

15.

Schuette, Wolfgang, A Gröschel, Martin Sebastian, et al.. (2013). A Randomized Phase II Study of Pemetrexed in Combination With Cisplatin or Carboplatin as First-Line Therapy for Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 14(3). 215–223. 39 indexed citations

16.

Sebastian, Martin. (2010). Review of catumaxomab in the treatment of malignant ascites. Cancer Management and Research. 2. 283–283. 19 indexed citations

17.

Schiller, Joan H., Joachim von Pawel, Philipp Schütt, et al.. (2010). Pemetrexed with or without Matuzumab as Second-Line Treatment for Patients with Stage IIIB/IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 5(12). 1977–1985. 45 indexed citations

18.

Schmittel, Alexander, Martin Sebastian, Ludwig Fischer von Weikersthal, et al.. (2009). Irinotecan plus carboplatin versus etoposide plus carboplatin in extensive disease small cell lung cancer: Results of the German randomized phase III trial. Journal of Clinical Oncology. 27(15_suppl). 8029–8029. 8 indexed citations

19.

Schuette, Wolfgang, Martin Sebastian, Stefan Andreas, et al.. (2009). 9079 Pemetrexed in combination with cisplatin or carboplatin in the first line therapy of locally advanced or metastatic non-small cell lung cancer: a randomized, two-arm, parallel, open-label, multicentric phase 2 study. European Journal of Cancer Supplements. 7(2). 528–529. 1 indexed citations

20.

Wittlinger, Thomas, et al.. (1999). A NONHEALING ULCER DIAGNOSED AS EXTRAMEDULLARY PLASMOCYTOMA OF THE LIMB EIGHT YEARS AFTER CARDIAC TRANSPLANTATION. Transplantation. 68(6). 901–904. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact